POSEIDON PHARMACEUTICAL UK LIMITEDActive

Company number 04987103Private limited companyIncorporated 2003

Key figures

−£450,640-15.1%
Net assets 2024/25
-600 k-400 k-200 k02020/212021/222022/232023/242024/25

Like most small UK companies, POSEIDON PHARMACEUTICAL UK LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
0500 k1 m2020/212021/222022/232023/242024/25
Filed accounts2020/21–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand16,12738,20734,720228,528115,140
Total assets255,943193,425217,666443,358373,056
Total liabilities387,006421,285574,461840,264829,343
Net assets / total equity-124,593-222,523-350,647-391,570-450,640
Average number of employees53333

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: POSEIDON PHARMACEUTICAL UK LIMITED

Company

POSEIDON PHARMACEUTICAL UK LIMITED is a private limited company registered with Companies House under company number 04987103. It was incorporated on 8 Dec 2003. Its status is active. The registered office is in Newport (TF10). Its nature of business (SIC 2007) is wholesale of pharmaceutical goods (46460).

Accounts

The latest accounts in the database are for 2024/25 (period ending 30 Sep 2025); the company files small company accounts (filleted). Net assets were −£450,640, down 15.1% on the previous year. Cash at bank and in hand was £115,140. Total assets were £373,056 and total liabilities £829,343. The company had an average of 3 employees. Figures are available for 5 financial years (2020/21–2024/25).

Control and charges

The company has 2 current directors. 3 persons with significant control are registered.

Filing deadlines

The next accounts are due by 30 Jun 2027. The next confirmation statement is due by 22 Dec 2026.